SCHEMBL16293189

SCHEMBL16293189

Cc1sc2nc(Cl)nc(N3CCC(C(O)C(O)C4CCN(c5nc(Cl)nc6scc(C(C)C)c56)CC4)CC3)c2c1C

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.38
LMNA P02545 4/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
POLB P06746 2/20 0.37
KDM4E B2RXH2 3/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
MAPT P10636 2/20 0.36
CHRM4 P08173 5/20 0.36
ESR1 P03372 1/20 0.36
HTT P42858 3/20 0.35
ALDH1A1 P00352 2/20 0.35
STAT3 P40763 1/20 0.34
HSD17B10 Q99714 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
RECQL P46063 1/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16293188 0.88 POLB (0.39) HPGDLMNASMN1; SMN2POLBKDM4E
SCHEMBL28087461 0.77 ESR1 (0.43) SMN1; SMN2ESR1ALDH1A1
SCHEMBL16293255 0.75 ESR1 (0.38) LMNASMN1; SMN2KDM4EESR1HTT
SCHEMBL14964997 0.72 KDM4E (0.47) HPGDLMNASMN1; SMN2POLBKDM4E
SCHEMBL27978720 0.71 CHRM4 (0.47) HPGDLMNASMN1; SMN2POLBKDM4E
SCHEMBL16293796 0.70 KDM4E (0.44) HPGDLMNASMN1; SMN2POLBKDM4E
SCHEMBL4556149 0.62 SMN1; SMN2 (0.43) HPGDLMNASMN1; SMN2POLBKDM4E
SCHEMBL11200448 0.61 ESR1 (0.60) ESR1
SCHEMBL11202279 0.61 ESR1 (0.49) SMN1; SMN2ESR1HTTALDH1A1
SCHEMBL27978693 0.58 MEN1 (0.45) HPGDLMNASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160152634-A1 THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2016-06-02 US disclosed
US-9290511-B2 Thieno-pyrimidines, useful as potassium channel inhibitors XENTION LIMITED (GB) 2016-03-22 US disclosed
US-20140371203-A1 Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors XENTION LIMITED (GB) 2014-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371203-A1 Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors KCNA3, KCNJ1, KCNJ11 HPGD 2232/4885LMNA 3153/4885SMN1; SMN2 3639/4885
US-20160152634-A1 THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS KCNA3, KCNJ1, KCNJ11 HPGD 2105/4885LMNA 3254/4885SMN1; SMN2 3669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.